Sanvar(R) (Debio 8609) For Esophageal Variceal Bleeding

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced that Debiovision Inc., its Canadian affiliate, filed its Complete Response to the approvable letter received from the United States (U.S.) Food and Drug Administration (FDA) for Sanvar(R), or Debio 8609 (vapreotide acetate).

More: continued here

Filed under: GastroIntestinal / Gastroentorology on November 7th, 2008